Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRME Stock Forecast 2025-2026
$1.30
Current Price
$170.68M
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PRME Price Targets
+1,284.6%
To High Target of $18.00
+784.6%
To Median Target of $11.50
+361.5%
To Low Target of $6.00
PRME Price Momentum
-17.2%
1 Week Change
-2.3%
1 Month Change
-76.8%
1 Year Change
-55.5%
Year-to-Date Change
-84.3%
From 52W High of $8.27
+16.6%
From 52W Low of $1.12
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Prime Medicine (PRME) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRME and similar high-potential opportunities.
Latest PRME Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, PRME has a bullish consensus with a median price target of $11.50 (ranging from $6.00 to $18.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $1.30, the median forecast implies a 784.6% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Debjit Chattopadhyay at Guggenheim, projecting a 1,284.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRME Analyst Ratings
11
Buy
1
Hold
0
Sell
PRME Price Target Range
Low
$6.00
Average
$11.50
High
$18.00
Current: $1.30
Latest PRME Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRME.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
| Mar 4, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Outperform | Reiterates | $10.00 |
| Mar 3, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
| Mar 3, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Dec 10, 2024 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $10.00 |
| Dec 3, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Reiterates | $18.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $10.00 |
| May 20, 2024 | HC Wainwright & Co. | Arthur He | Buy | Initiates | $10.00 |
| May 16, 2024 | Citigroup | Samantha Semenkow | Buy | Upgrade | $10.00 |
| May 13, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $15.00 |
| May 7, 2024 | Jefferies | Maury Raycroft | Buy | Assumes | $15.00 |
| Apr 23, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $12.00 |
| Apr 22, 2024 | Chardan Capital | Geulah Livshits | Buy | Initiates | $17.00 |
| Apr 8, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $0.00 |
| Apr 3, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $12.00 |
| Apr 2, 2024 | Wedbush | David Nierengarten | Outperform | Initiates | $12.00 |
| Mar 8, 2024 | JP Morgan | Overweight | Maintains | $0.00 |
Prime Medicine Inc. (PRME) Competitors
The following stocks are similar to Prime Medicine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PRME
Prime Medicine
mkt cap
170.68M
Prime Medicine Inc. (PRME) Financial Data
Prime Medicine Inc. has a market capitalization of $170.68M with a P/E ratio of 0.0x. The company generates $3.85M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +146.0% quarter-over-quarter, while maintaining an operating margin of -3,603.3% and return on equity of -115.2%.
Valuation Metrics
Market Cap
$170.68M
Enterprise Value
$143.06M
P/E Ratio
0.0x
PEG Ratio
-0.9x
Price/Sales
44.4x
Growth & Margins
Revenue Growth (YoY)
+146.0%
Gross Margin
N/A
Operating Margin
-3,603.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+86.8%
Current Ratio
4.8x
Debt/Equity
113.3x
ROE
-115.2%
ROA
-40.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Prime Medicine Inc. (PRME) Business Model
About Prime Medicine Inc.
What They Do
Develops advanced gene editing technology.
Business Model
The company focuses on prime editing, a cutting-edge gene editing technology that allows for precise corrections of genetic mutations without damaging the DNA structure. Prime Medicine generates revenue through partnerships, collaborations, and potentially licensing agreements with pharmaceutical companies, aiming to create therapeutics for various genetic disorders.
Additional Information
Prime Medicine is positioned in the biotechnology and healthcare sectors, working to transform the treatment landscape for challenging genetic diseases. With a commitment to improving patient outcomes, the company's innovative approach may significantly advance the field of personalized medicine and gene therapy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
214
CEO
Dr. Keith Michael Gottesdiener M.D., Ph.D.
Country
United States
IPO Year
2022
Website
primemedicine.comPrime Medicine Inc. (PRME) Latest News & Analysis
Latest News
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
4 days ago
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) expects Phase 1/2 trial data for PM359 in 2025, with IND/CTA filings for PM577 in 1H 2026 and AATD program in mid-2026. Financial results for Q1 2025 were also reported.
Why It Matters
The timeline for clinical trials and regulatory filings indicates future revenue potential for Prime Medicine, affecting stock valuations and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prime Medicine, Inc. (PRME) reported a quarterly loss of $0.40 per share, exceeding the Zacks estimate of a $0.32 loss, but an improvement from a $0.44 loss a year prior.
Why It Matters
PRME's larger-than-expected loss signals potential financial struggles, impacting investor confidence and stock performance. Year-over-year improvement may offer some reassurance, but concerns remain.
Source: Zacks Investment Research
Market Sentiment:
Negative
Why Prime Medicine Stock Is Soaring Today
1 month ago
Quick Summary
Prime Medicine's shares rose 10.5% on Thursday, reflecting a significant increase in stock value for the gene-editing company.
Why It Matters
Prime Medicine's stock surge indicates strong investor confidence and potential positive developments in gene editing, which could impact future growth and valuation.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Prime Medicine (PRME) shares rose over 12% this week following news of a new investigational program, driven by bullish investor sentiment, according to S&P Global Market Intelligence.
Why It Matters
The fresh investigational program at Prime Medicine is boosting investor confidence, leading to a significant stock price increase, signaling potential growth and profitability.
Source: The Motley Fool
Market Sentiment:
Positive
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
1 month ago
Quick Summary
Prime Editing is emerging as a leading approach for AATD, utilizing a proprietary liver platform with a universal liver LNP, indicating potential for significant advancements in treatment.
Why It Matters
Prime Editing's potential as a leading treatment for AATD and the emergence of a new liver platform could signify breakthroughs, affecting future valuations and market positions of related biotech firms.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Prime Medicine, Inc. (Nasdaq: PRME) plans to report initial Phase 1/2 trial data for PM359 in 2025 and file IND for PM577 in 1H 2026, while advancing other preclinical programs.
Why It Matters
Prime Medicine's clinical trial advancements and upcoming IND filings signal potential breakthroughs in rare diseases, which could drive stock value and investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRME Stock
What is Prime Medicine Inc.'s (PRME) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, Prime Medicine Inc. (PRME) has a median price target of $11.50. The highest price target is $18.00 and the lowest is $6.00.
Is PRME stock a good investment in 2025?
According to current analyst ratings, PRME has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRME stock?
Wall Street analysts predict PRME stock could reach $11.50 in the next 12 months. This represents a 784.6% increase from the current price of $1.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Prime Medicine Inc.'s business model?
The company focuses on prime editing, a cutting-edge gene editing technology that allows for precise corrections of genetic mutations without damaging the DNA structure. Prime Medicine generates revenue through partnerships, collaborations, and potentially licensing agreements with pharmaceutical companies, aiming to create therapeutics for various genetic disorders.
What is the highest forecasted price for PRME Prime Medicine Inc.?
The highest price target for PRME is $18.00 from Debjit Chattopadhyay at Guggenheim, which represents a 1,284.6% increase from the current price of $1.30.
What is the lowest forecasted price for PRME Prime Medicine Inc.?
The lowest price target for PRME is $6.00 from at , which represents a 361.5% increase from the current price of $1.30.
What is the overall PRME consensus from analysts for Prime Medicine Inc.?
The overall analyst consensus for PRME is bullish. Out of 16 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are PRME stock price projections?
Stock price projections, including those for Prime Medicine Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 11:38 AM UTC